Pancreatoduodenectomy following neoadjuvant chemoradiation therapy in uncinate process pancreatic cancer

Chang Moo Kang, Jin Young Choi, Jin Sil Seong, Si Young Song, Woo Jung Lee, Myung Jin Kim, Jae Bock Chung

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

OBJECTIVE: The objective of the study was to delineate surgical outcomes of pancreatoduodenectomy following neoadjuvant concurrent chemoradiation therapy (CCRT) in uncinate process pancreatic cancer (UPC). METHODS: We reviewed 97 patients with resected usual pancreatic head cancer (PHC) and UPC and analyzed clinicopathologic characteristics and survival outcomes of PHC and UPC with a review of the reported literature regarding UPC. RESULTS: Twenty-five patients (27.8%) had UPC, and 72 patients had PHC. Pylorus-preserving pancreatoduodenectomy was performed in 67 patients (69.1%) and conventional pancreatoduodenectomy in 28 patients (28.9%), and 2 patients needed total pancreatectomies. When comparing UPCs with PHCs, less frequent jaundice (P = 0.009) and more advanced stages of cancers at the time of diagnosis (linear-to-linear association, P = 0.03) were found in UPCs, and CCRT was administered more frequently in UPCs (P = 0.013). Survival outcomes between PHC and UPC were similar, with median survival rates of 25.9 and 30.5 months, respectively (P = 0.702). In addition, disease-free survival was similar between the 2 groups (15.6 and 15.2 months, respectively; P = 0.4503). Our oncologic outcome of pancreatectomy for UPC is likely to be more acceptable compared with those previously reported in the literature. CONCLUSIONS: Although UPCs are found in relatively advanced clinical stages, favorable oncologic outcomes may be obtained by pancreatectomy following preoperative CCRT.

Original languageEnglish
Pages (from-to)467-473
Number of pages7
JournalPancreas
Volume41
Issue number3
DOIs
Publication statusPublished - 2012 Apr 1

Fingerprint

Neoadjuvant Therapy
Pancreaticoduodenectomy
Pancreatic Neoplasms
Head and Neck Neoplasms
Pancreatectomy
Survival
Pylorus
Jaundice
Disease-Free Survival
Therapeutics
Survival Rate

All Science Journal Classification (ASJC) codes

  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism
  • Hepatology
  • Endocrinology

Cite this

Kang, Chang Moo ; Choi, Jin Young ; Seong, Jin Sil ; Song, Si Young ; Lee, Woo Jung ; Kim, Myung Jin ; Chung, Jae Bock. / Pancreatoduodenectomy following neoadjuvant chemoradiation therapy in uncinate process pancreatic cancer. In: Pancreas. 2012 ; Vol. 41, No. 3. pp. 467-473.
@article{bbad242aab9e46b4aafdc3ae5a80348b,
title = "Pancreatoduodenectomy following neoadjuvant chemoradiation therapy in uncinate process pancreatic cancer",
abstract = "OBJECTIVE: The objective of the study was to delineate surgical outcomes of pancreatoduodenectomy following neoadjuvant concurrent chemoradiation therapy (CCRT) in uncinate process pancreatic cancer (UPC). METHODS: We reviewed 97 patients with resected usual pancreatic head cancer (PHC) and UPC and analyzed clinicopathologic characteristics and survival outcomes of PHC and UPC with a review of the reported literature regarding UPC. RESULTS: Twenty-five patients (27.8{\%}) had UPC, and 72 patients had PHC. Pylorus-preserving pancreatoduodenectomy was performed in 67 patients (69.1{\%}) and conventional pancreatoduodenectomy in 28 patients (28.9{\%}), and 2 patients needed total pancreatectomies. When comparing UPCs with PHCs, less frequent jaundice (P = 0.009) and more advanced stages of cancers at the time of diagnosis (linear-to-linear association, P = 0.03) were found in UPCs, and CCRT was administered more frequently in UPCs (P = 0.013). Survival outcomes between PHC and UPC were similar, with median survival rates of 25.9 and 30.5 months, respectively (P = 0.702). In addition, disease-free survival was similar between the 2 groups (15.6 and 15.2 months, respectively; P = 0.4503). Our oncologic outcome of pancreatectomy for UPC is likely to be more acceptable compared with those previously reported in the literature. CONCLUSIONS: Although UPCs are found in relatively advanced clinical stages, favorable oncologic outcomes may be obtained by pancreatectomy following preoperative CCRT.",
author = "Kang, {Chang Moo} and Choi, {Jin Young} and Seong, {Jin Sil} and Song, {Si Young} and Lee, {Woo Jung} and Kim, {Myung Jin} and Chung, {Jae Bock}",
year = "2012",
month = "4",
day = "1",
doi = "10.1097/MPA.0b013e31822a68bc",
language = "English",
volume = "41",
pages = "467--473",
journal = "Pancreas",
issn = "0885-3177",
publisher = "Lippincott Williams and Wilkins",
number = "3",

}

Pancreatoduodenectomy following neoadjuvant chemoradiation therapy in uncinate process pancreatic cancer. / Kang, Chang Moo; Choi, Jin Young; Seong, Jin Sil; Song, Si Young; Lee, Woo Jung; Kim, Myung Jin; Chung, Jae Bock.

In: Pancreas, Vol. 41, No. 3, 01.04.2012, p. 467-473.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Pancreatoduodenectomy following neoadjuvant chemoradiation therapy in uncinate process pancreatic cancer

AU - Kang, Chang Moo

AU - Choi, Jin Young

AU - Seong, Jin Sil

AU - Song, Si Young

AU - Lee, Woo Jung

AU - Kim, Myung Jin

AU - Chung, Jae Bock

PY - 2012/4/1

Y1 - 2012/4/1

N2 - OBJECTIVE: The objective of the study was to delineate surgical outcomes of pancreatoduodenectomy following neoadjuvant concurrent chemoradiation therapy (CCRT) in uncinate process pancreatic cancer (UPC). METHODS: We reviewed 97 patients with resected usual pancreatic head cancer (PHC) and UPC and analyzed clinicopathologic characteristics and survival outcomes of PHC and UPC with a review of the reported literature regarding UPC. RESULTS: Twenty-five patients (27.8%) had UPC, and 72 patients had PHC. Pylorus-preserving pancreatoduodenectomy was performed in 67 patients (69.1%) and conventional pancreatoduodenectomy in 28 patients (28.9%), and 2 patients needed total pancreatectomies. When comparing UPCs with PHCs, less frequent jaundice (P = 0.009) and more advanced stages of cancers at the time of diagnosis (linear-to-linear association, P = 0.03) were found in UPCs, and CCRT was administered more frequently in UPCs (P = 0.013). Survival outcomes between PHC and UPC were similar, with median survival rates of 25.9 and 30.5 months, respectively (P = 0.702). In addition, disease-free survival was similar between the 2 groups (15.6 and 15.2 months, respectively; P = 0.4503). Our oncologic outcome of pancreatectomy for UPC is likely to be more acceptable compared with those previously reported in the literature. CONCLUSIONS: Although UPCs are found in relatively advanced clinical stages, favorable oncologic outcomes may be obtained by pancreatectomy following preoperative CCRT.

AB - OBJECTIVE: The objective of the study was to delineate surgical outcomes of pancreatoduodenectomy following neoadjuvant concurrent chemoradiation therapy (CCRT) in uncinate process pancreatic cancer (UPC). METHODS: We reviewed 97 patients with resected usual pancreatic head cancer (PHC) and UPC and analyzed clinicopathologic characteristics and survival outcomes of PHC and UPC with a review of the reported literature regarding UPC. RESULTS: Twenty-five patients (27.8%) had UPC, and 72 patients had PHC. Pylorus-preserving pancreatoduodenectomy was performed in 67 patients (69.1%) and conventional pancreatoduodenectomy in 28 patients (28.9%), and 2 patients needed total pancreatectomies. When comparing UPCs with PHCs, less frequent jaundice (P = 0.009) and more advanced stages of cancers at the time of diagnosis (linear-to-linear association, P = 0.03) were found in UPCs, and CCRT was administered more frequently in UPCs (P = 0.013). Survival outcomes between PHC and UPC were similar, with median survival rates of 25.9 and 30.5 months, respectively (P = 0.702). In addition, disease-free survival was similar between the 2 groups (15.6 and 15.2 months, respectively; P = 0.4503). Our oncologic outcome of pancreatectomy for UPC is likely to be more acceptable compared with those previously reported in the literature. CONCLUSIONS: Although UPCs are found in relatively advanced clinical stages, favorable oncologic outcomes may be obtained by pancreatectomy following preoperative CCRT.

UR - http://www.scopus.com/inward/record.url?scp=84859104281&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84859104281&partnerID=8YFLogxK

U2 - 10.1097/MPA.0b013e31822a68bc

DO - 10.1097/MPA.0b013e31822a68bc

M3 - Article

C2 - 22158068

AN - SCOPUS:84859104281

VL - 41

SP - 467

EP - 473

JO - Pancreas

JF - Pancreas

SN - 0885-3177

IS - 3

ER -